Report period | 2017 | 2018 | 2019 | 2020 | 2021 | Q2 22 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, HK$ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
1177:HK | Sino Biopharmaceutical Limited | Common share | - | KYG8167W1380 | HK$2.91 |
Company name | Sino Biopharmaceutical |
---|---|
Tags | #hong_kong_spb |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | Office Tower Unit 09, 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong |
Mailing address | Office Tower Unit 09, 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong |
Website | www.sinobiopharm.com |